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Stem cells are unspecialized/undifferentiated cells that exist in embryos and adult tissues or can be converted from
somatic differentiated cells. Use of stem cells for tissue regeneration and tissue engineering has been a cornerstone
of the regenerative medicine. Stem cells are also believed to exist in cancer tissues, namely cancer stem cells (CSCs).
Growing evidence suggests that CSCs are the culprit of cancer dormancy, progression and recurrence, and thus
have recently received great attention. MicroRNAs (miRNAs) are a group of short, non-coding RNAs that regulate
expression of a wide range of genes at a post-transcriptional manner. They are emerging as key regulators of stem
cell behaviors. This mini review summarizes the basic biogenesis and mode of actions of miRNAs, recent progress
and discoveries of miRNAs in cellular reprogramming, stem cell differentiation and cellular communication, as well
as miRNAs in CSCs. Some potential of miRNAs in future biomedical applications and research pertaining to stem
cells are briefly discussed.
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Background
MicroRNAs (miRNAs) are short (typically 20–26 nucleo-
tides), non-coding RNAs generated from genomic DNA, and
they generally exert negative post-transcriptional regulation
(including translational repression, mRNA destabilization,
and/or mRNA cleavage) by binding to target mRNAs via
the RNA-induced silencing complex (RISC) although up-
regulation of gene expression by miRNAs has been reported
[1, 2]. Studies have revealed that a minimum of 6 bp
miRNA:mRNA match (seed sequence) is sufficient to
suppress gene expression [3, 4]. Such an imperfect match
mode of action allows a given miRNA to target more
mRNAs. In general, each miRNA can target many mRNAs
(up to more than 100 mRNAs), and multiple miRNAs can
regulate a single gene/mRNA [5, 6]. Hence, dysregulating
even one miRNA may disrupt the diligent balance of many
cellular systems or pathways, which lead to development of
diseases or disorders, such as cancers and cardiovascular dis-
eases. Analysis of miRNA expression can find out the prob-
lematic miRNAs, which can be the therapeutic targets for
curing certain disorders by restoring the dysregulated
miRNAs. In addition, miRNAs have been found in many
body fluids (blood, urine, milk, saliva, and cerebrospinal
fluid), known as circulating miRNAs [7]. These circulating
miRNAs (such as miR-21 and miR-181a in human breast
milk) are pretty stable and resistant to ribonuclease (RNase)
digestion [8]. They may serve as good biomarkers for
disease diagnosis [9, 10]. This topic is currently being
intensively investigated.
Study of miRNA biology is important on our under-
standing of the regulation of a wide array of cell functions
by miRNAs. Growing evidence shows that miRNAs are a
key player in regulating cell differentiation, growth, mobil-
ity and apoptosis, and miRNAs have emerged as critical
molecular regulators for maintaining the functions of stem
cells by fine tuning the protein levels of various factors.
Because miRNAs contribute to the specification or
differentiation of many cell types, studying miRNAs allows
us to understand how miRNAs control the differentiation
of stem cells and to elucidate molecular mechanism of
cellular differentiation, such as what genes are turned on
and off or changing their expression during the differenti-
ation, as well as the molecular networks in controlling cell
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differentiation. Understanding the regulation of miRNA
biogenesis and their mechanism in controlling stem cell
differentiation and cell fate determination would facili-
tate the development of therapeutic approaches in ap-
plication of stem cells in tissue regeneration and tissue
engineering.
MicroRNA biogenesis and their therapeutic principle
miRNAs are generated from long double-stranded RNAs.
In particular within cells, the miRNA machinery is acti-
vated by long double-stranded RNAs to process the RNAs
into short miRNAs. Theoretically, any transcript that
contains a region of sufficient complementary pairs cap-
able to form a long double-stranded fragment structure
can serve as a precursor for miRNAs biogenesis. It should
be mentioned that perfect complimentary match is not
necessary in the long double stranded region, and few
mismatch pairs in the long double-stranded RNA are
allowed for activation of the miRNA pathway. Figure 1 il-
lustrates the possibilities of biogenesis of miRNAs in cells.
Specifically, miRNAs can be generated by their own genes
or by the part of sequences of the protein-coding genes.
Primary miRNAs (pri-miRNAs) can be transcribed as
polycistronic transcripts (containing multiple hairpin
structures in one RNA transcript) or as individual tran-
scripts from intergenic regions, exonic or intronic se-
quences [11]. On the basis of the location of the miRNA
generation, miRNAs are grouped into two classes [12]: (A)
Intergenic miRNAs are generated from transcripts of
miRNA genes located between protein-coding genes; (B)
Intragenic miRNAs are generated from transcripts of
sequences located within the protein-coding genes
(Fig. 1).
During the miRNA biogenesis, the complimentary
RNA sequence is folded into stem and loop structures
and then processed to hairpin-shaped premature miRNA
(known as pre-miRNA) by a Class 2 ribonuclease III
enzyme, Drosha within the nucleus. The hairpin pre-RNA
is exported from the nucleus to the cytoplasm by
Exportin-5. Next, the pre-miRNA is processed into ma-
ture miRNAs by Dicer. Several proteins are then recruited
to form RNA induced silencing complex (RISC) with one
strand removed and one strand preserved as a guide
strand, which can complementarily bind to target mRNAs
Fig. 1 Schematic illustration of microRNA (miRNA) biogenesis from transcription of a protein coding gene and from a miRNA gene. During
miRNA biogenesis, a RNA transcript forms stem-loop primary-miRNAs (pri-miRNAs) that can be polycistronic or singular. The pri-miRNAs are
processed into hairpin premature-miRNAs (pre-miRNAs) by Drosha. Pre-miRNAs are further cleaved into mature miRNAs by Dicer. Based on their
origination, miRNAs can be classified into intragenic miRNAs that are originated from protein coding genes, and intergenic miRNAs that are
originated from miRNA genes located between protein coding genes
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causing translational repression, mRNA destabilization,
and/or mRNA cleavage for post-transcriptional regulation
of protein synthesis (Fig. 2). After examining the responses
of thousands of genes to miRNAs, Baek et al. concluded
that most miRNA target sites are located in the 3′ un-
translated regions (3′UTR) of mRNA transcripts [13].
However, other studies demonstrated that miRNA target
sites can reside beyond the 3′ UTR in the protein coding
sequences (CDS) of mRNA [14]. Some pre-miRNAs and
mature miRNAs can be secreted from cells into the
extracellular environment (Fig. 2) becoming circulating
miRNAs [15] to exert their function/role in other cells
within the tissue or in different tissues.
Because of the important role and functions of miRNAs
in regulating many aspects of the cellular processes relating
to disease development, miRNAs provide new therapeutic
targets for drug development in curing many diseases.
Generally, miRNA-based therapeutics can be either miRNA
antagonists or miRNA mimics. While miRNA antagonists
can be used to inhibit the miRNAs that cause diseases,
miRNA mimics can be used to increase or restore amount
of the miRNAs whose expression is deficient leading to
development of the diseases. For example, triple-negative
breast cancer (TNBC) is an aggressive subtype of breast
cancer. miRNA-profiling studies identified that miR-34a
expression was lost in mesenchymal and mesenchymal-
stem cell like subtypes of TNBC [16], and lack of miR34a
causes significant increased expression of the genes targeted
by miR-34a in the cancer cells. Restoration of miR34a
expression could significantly decrease proliferation and
invasion, and activate senescence of the cancer cells.
Currently, miR-34a replacement therapy is being tested
in human clinical trials as a promising therapeutic
strategy for TNBC [16]. miRNA-based therapies are also
considered for treating or preventing infectious diseases.
For example, miR-122 is critical for the replication of
Fig. 2 Step-by-step illustration of miRNA pathway in regulating gene expression within a eukaryotic cell: (1) Transcription of DNA into pri-miRNA.
(2) Dorsha processes pri-mRNA into pre-miRNA (hairpin shape). (3) Pre-miRNA is transported to cytoplasm by Exportin-5. (4a) pre-miRNAs can be
released from the cytoplasm into extracellular environment, or (4b) Pre-miRNA is processed by Dicer to generate mature miRNA duplex in the
cytoplasm. (5a) Binding miRNA to proteins to form RNA-induced silencing complex (RISC)*. One of the double strands (i.e., the passenger strand)
is removed, and only the guide strand is present, or (5b) secretion of mature miRNAs to outside of the cell. (6a) RISC binds to mRNA with perfect
match. (6b) RISC binds to mRNA with some mismatches. (7a) mRNA degradation when the RISC binds to a perfect match mRNA sequence, or
(7b,c) either translation inhibition, or mRNA deadenylation leading to mRNA destabilization when some mismatches of mRNA sequence and the
RISC. *RISC is also known as miRISC in miRNA-mediated RNA interference pathway
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hepatitis C virus (HCV) [17, 18] by direct interaction
with the viral RNA [18]. So miR-122 inhibitors may be
prescribed as antiviral intervention treatment for HCV
infection in the future [17]. The recent discoveries and
breakthroughs in miRNAs indicate that miRNAs may
have broad and tremendous impacts in many aspects of
biology and medicine. This review summarizes only few
important fields of miRNAs that impact stem cell repro-
gramming, differentiation (Fig. 3, Table 1), and cancer
stem cells as well. The emerging field of miRNAs in cell
communication is also briefly discussed.
MicroRNAs in cell reprogramming
Since the invention of induced pluripotent stem cells
(iPSCs) by forced overexpression of the defined transcrip-
tion factors, intensive studies have been carried out to
evaluate therapeutic applications of this technique. One
major drawback of the traditional DNA-based reprogram-
ming is the random insertion of the reprogramming fac-
tors into the genome in the iPSCs, which could lead to
their genome disruption. Extensive research has been con-
ducted to modify the approaches to improve efficiency and
safety of the iPSCs using different combinations of tran-
scription factors, delivery methods or using non-genetic
approaches, such as using small molecules to induce pluri-
potency. MicroRNA analysis defined that embryonic stem
cells (ESCs) and iPSCs have a distinct miRNA expression
pattern as compared to the differentiated somatic cells
[19]. This has promoted the research using miRNAs for
cellular reprogramming. Human ESCs express abundant
miR-302 family, including miR-302a, miR-302a*, miR-302b,
miR-302b*, miR-302c, miR-302c* and miR-302d with a
highly conserved sequence [20]. Transient transfection of
the miR-302s into human cancer cell lines resulted in the
conversion of the cells into pluripotent state expressing
key ESC markers, such as Oct3/4, SSEA-3, SSEA-4, Sox2
and Nanog (Fig. 3), and having a highly demethylated
genome similar to a reprogrammed zygotic genome [21].
Ectopic overexpression of ESC specific miRNAs in som-
atic cells successfully dedifferentiated the cells into the
stem cell stage. For example, Miyoshi et al. reported that a
set of three miRNAs (miR-302s, miR-369s and miR-200c)
selected from miRNAs that are highly expressed in iPSCs
and/ESCs are capable of reprogramming mouse and
human somatic cells [22]. The iPSCs induced by miRNAs
display similar characteristics as the iPSCs induced by
Oct4/Sox2/Klf4/Myc (OSKM). This miRNA-mediated cell
reprogramming technique was claimed to be more
efficient than the standard OSKM overexpression me-
thods [23]. Because of no concerns of genome integration
of miRNAs, miRNA-mediated cell reprogramming may
provide an alternative and likely a safer approach for
generation of iPSCs as compared to the traditional
DNA-based cell reprogramming methods.
The importance of miRNAs in cell reprogramming is
also supported by another study demonstrating that the
Dicer-knockout fibroblasts (i.e., fibroblasts without mature
miRNAs) could not be reprogrammed into iPSCs using
the traditional reprogramming factor overexpression
method. This suggests that miRNAs are indispensable for
Fig. 3 The roles of miRNAs in regulating pluripotency factors in reprogramming differentiated/somatic cells for iPSC production and in stem cell
differentiation. In general, miRNAs promote cell reprogramming by enhancing expression of pluripotency factors whereas they enhance stem cell
differentiation by inhibiting expression of pluripotency factors
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cellular reprogramming [24]. While miRNAs facilitating
cell reprogramming for generation of iPSCs have been
studied, miRNAs that inhibit cell reprogramming were
also discovered. It is expected that miRNAs targeting to
directly or indirectly reduce the expression of pluripotent
genes will suppress or reduce the cellular reprogramming.
In this regard, miR-34s (miR-34a, b, c) was found to
suppress somatic cell reprogramming by repressing
expression of Nanog, Sox2 and N-Myc [25].
The mechanisms of the miRNA-mediated cell repro-
gramming are not fully understood. It was reported that
exogenous Oct4 and Sox2 can bind the promoter regions
of miRNA genes to activate the transcription of miR-141/
200c and miR-200a/b/429 cluster [26]. Suppression of
miR-200 decreased the efficiency of OSKM (OCT4,
SOX2, KLF4 and MYC)-induced iPSC generation,
whereas forced overexpression of miR-200s using retro-
viral vector enhanced OSKM reprogramming efficiency by
twofold as compared to OSKM only group. Further
analysis indicated that miR-200 enhanced OSKM repro-
gramming efficiency by binding to 3′UTR of the mRNA
of zinc finger E-box binding homeobox 2 (ZEB2) to
reduce ZEB2 expression [26]. The miRNAs reported to
affect cell reprogramming are listed in the Table 1.
Table 1 Functions and roles of miRNAs in stem cell reprogramming and differentiation
microRNAs (miR) Function Cell type Reference
miR-1 and miR-499 Cardiac muscle regeneration Cardiomyocyte progenitor cells [39]
miR-15, miR-29, miR-100, miR-133,
miR-199, miR-208
Cardiac development [40] (review)
miR-16, miR-103, miR-107 Inhibit stem cell proliferation HSCs [31]
miR-22 Smooth muscle cell (SMC) differentiation ESC, adventitia stem cells [37]
miR-26a Modulated osteoblast differentiation by
targeting Smad1 gene
hADSCs [34, 35]
miR-26a and -26b Promote adipogenic differentiation hADSCs [82]
miR-29 Regulate collagen production for tendon
regeneration and remodeling
Tenocytes [38]
miR-34 s (miR-34a, b, c) Suppress cell reprogramming Somatic cells [25]
miR-125b Inhibit osteoblast differentiation mMSC [33]
miR-128, miR-181 Inhibit stem cell differentiation HSCs [31]
miR-134, miR-296, miR-470 Target Nanog, Oct4 (Pou5f1) and Sox2 mESCs [14]
miR-143, miR-145 Vascular smooth muscle differentiation. NCSCs [12]
miR-145 Promote differentiation by downregulating
the pluripotency genes, OCT4, SOX2,
and KLF4
hESCs [29]
miR-181 Promote differentiation by targeting Lin28. HSCs [83]
miR-200 family (a) Suppress Sox2 and E2F3 to promote
differentiation into neurons.
(b) Promote mesenchymal-epithelial transition
(MET) to enhance OSKM-induced
reprogramming.
(a) Neural progenitors; (b) Fibroblast (a) [84]; (b) [26]
miR-200c, miR-302 s, miR-369 s Reprogramming somatic cells to iPSCs Somatic cells [22]
miR-290 cluster (miR-291-3p, miR-294,
miR-295)
Substitute for c-Myc. MEFs [85]
Increase efficiency of Oct4, Klf4 and Sox2
(OKS) reprogramming
miR-302s Conversion of cancer cells to pluripotency. Cancer cells [21]
miR-302a Regulate cell cycle by targeting Cyclin D1 hESCs [86]
miRNA-302/367 cluster Reprogram cells into neurons Fibroblasts [72]
miR-378 Stem cell survival and vascularization MSCs [41]
miR-720 Promote differentiation by repressing the
expression of Nanog gene.
DPSCs [27]
Abbreviations: DPSCs dental pulp stem cells, hADSCs human adipose tissue-derived stem cells, HSCs hematopoietic stem cells, hESCs human embryonic stem cells,
mESCs mouse embryonic stem cells, MEFs mouse embryonic fibroblasts, NCSCs neural crest stem cells, MET mesenchymal-to-epithelial transition, mMSC mouse
mesenchymal stem cells, OSKM OCT4, SOX2, KLF4 and MYC
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MicroRNAs in stem cell differentiation and tissue
regeneration
A side population (SP) is a sub-population of cells sorted
with particular markers from a given population. Certain
SP, such as Hoechst SP contains high percentages of
stem cells. With a locked nucleic acid (LNA)-based
miRNA array, miR-720 was found to be highly expressed
in the differentiated main population (MP) cells of
dental pulp cells as compared to that in the SP cells also
derived from the dental pulp cells [27]. Further studies
showed that miR-720 represses the expression of the
pluripotent determinant gene, Nanog in the dental pulp
cells, and repressing Nanog could promote differenti-
ation of dental pulp stem/progenitor cells [27]. In an
miRNA profiling study, Hu et al. [28] identified unique
subsets of miRNAs that were gradually up- or down-
regulated in ESCs during retinal pigment epithelium
differentiation, and downregulation of the subset of
miRNAs was associated with upregulation of retinal pig-
ment epithelium-specific genes. Xu et al. [29] reported
that human embryonic stem cells (hESCs) increase miR-
145 expression during differentiation because miR-145
can directly target the 3′UTR of the pluripotency factor
genes, OCT4, SOX2, and KLF4 leading to repressing ex-
pression of those genes. Downregulation of the expression
of the pluripotency genes decreases self-renewal of the
ESCs and induces lineage-restricted differentiation (Fig. 3).
A long intergenic noncoding RNA, linc-RoR, containing
miR-145 binding sites can act as a natural miRNA sponge
to sequestrate miR-145. In turn, miR-145 sequestration
prevents miR145-mediated downregulation of self-renewal
transcription factors Nanog, Oct4, and Sox2 in human
ESCs [30].
miRNAs can function in maintaining adult stem cell
fate via multiple avenues. In hematopoietic stem cells
(HSCs), expression of miR-128 and miR-181 prevents
differentiation whereas expression of miR-16, miR-103,
and miR-107 inhibits proliferation [31]. miRNAs have
been reported to regulate various differentiation path-
ways including myogenesis, cardiogenesis, neurogenesis,
and osteogenesis [32]. One study reported that overex-
pression of miR-125b inhibited osteoblast differentiation
by reducing cell proliferation in mouse mesenchymal
stem cells [33]. Bone marrow-derived mesenchymal stem
cells (BMSCs) and adipose tissue-derived mesenchymal
stem cells (ADSCs) are intensively studied because of
their high accessibility. It has been shown that miR-26a
is an important miRNA in regulating osteogenic differ-
entiation of BMSCs and ADSCs. In particular, osteogenic
differentiation of ADSCs was inhibited because miR-26a
repressed the translation of Smad1, a transcription factor
required for osteogenesis [34, 35]. Interestingly, miR-26
family was found to increase adipogenic differentiation
of human ADSCs by targeting ADAM metallopeptidase
domain 17 (ADAM17) [28]. A recent publication re-
ported distinct targeting patterns of miR-26 in BMSCs
and ADSCs. Specially, miR-26a mainly targeted on
GSK3β to activate Wnt signaling for promoting osteo-
genic differentiation in BMSCs, whereas in ADSCs, it
targeted osteogenic transcription factor Smad1 to sup-
press BMP signaling to interfere the osteogenic differen-
tiation [35].
miR-22 is a highly-conserved miRNA with multi-
functions/roles in epigenetic modification, embryonic
development and stem cell differentiation, and it also
influences tumorigenesis and development of human dis-
eases/disorders [36]. During smooth muscle cell (SMC)
differentiation, miR-22 level is significantly increased.
Transfection of miR-22 mimic to overexpress miR-22 in
ESCs or adventitia stem/progenitor cells resulted in en-
hancement of SMC differentiation whereas knockdown of
miR-22 by its antagomiR inhibited SMC differentiation,
suggesting that miR-22 plays important role in SMC dif-
ferentiation. Further study indicated that miR-22 exerts
such effect via directly targeting and down-regulating
Methyl CpG-binding protein 2 (MECP2) expression [37].
The possibility of using miRNAs for improvement of
tissue regeneration is currently under investigation. A
research team in the University of Glasgow found that
miR-29a has potential for tendon regeneration by inter-
acting with interleukin-33 to regulate the production of
collagen [38]. Other miRNAs, such as miR-1 and miR-499
were reported to improve differentiation of transplanted
stem/progenitor cells for cardiac muscle regeneration
[39]. Many other miRNAs, including miR-133, miR-15,
miR-29, miR-100, miR-199, miR-208 and miR-378 were
reported to be involved in cardiac development, vascu-
larization or cardiomyocyte proliferation [40, 41]. Table 1
summarizes the miRNAs that are involved in stem cell re-
programming and differentiation.
MicroRNAs in cancer stem cells
Cancer stem cells (CSCs) are believed to be the culprit
of the cancer dormancy, initiation and development.
Although many sophisticated treatments are available in
fighting cancers, survival rate is still pretty low in many
cancers. Some proposed that the low survival rate may
be due to post-treatment enrichment of the CSCs which
is a sub-population of drug resistant tumor cells with
abilities of self-renewal, cancer initiation, and further
maintenance of tumors [42]. The fact that most malig-
nancies showed dysregulated miRNAs has promoted the
effort to study the association between miRNAs and
cancers. Numerous recent publications have demon-
strated the roles of miRNAs, such as miR-132, miR-182,
miR-342 and miR-1225 in cancer cell proliferation,
migration, invasion and metastasis [43–47]. Several re-
views summarized the association and functions of
Yao Biological Procedures Online  (2016) 18:8 Page 6 of 10
miRNAs in initiation, progression, metastasis or prognosis
of various cancers [48–52]. A searchable database
has been established to facilitate the research of cancer-
related miRNAs (http://mircancer.ecu.edu/). miRNAs
were found to be important in regulating CSCs [53].
This has been demonstrated with osteosarcoma-derived
CSCs in a recent publication reporting that overexpres-
sion of miRNA let-7d decreased CCND2 and E2F2 cell-
cycle-activators and increased p21 and p27 CDK-
inhibitors, which cause reduced CSC proliferation. Let-7d
overexpression also decreased the expression of pluripo-
tent (or stemness) genes, Oct3/4, Sox2, Nanog, Lin28B
and HMGA2 [54].
CSCs can be viewed as generated from the process of
dedifferentiation of somatic cells, which is a similar
process as cellular reprogramming [55]. Thus, it has
been proposed to use miRNAs that can reduce cellular
reprogramming to suppress formation of CSCs. CSCs
also show dysregulated miRNA expression, targeting
such dysregulated miRNAs by miRNA mimics or
miRNA inhibitors is currently under investigation for
the development of innovative miRNA-based therapy
against CSCs [56]. miR-21 was found to be significantly
elevated in colorectal cancer, and Deng et al. reported
that knockdown of miR-21 could increase the sensitivity
of colorectal cancer cells to a classic cancer chemothera-
peutic drug, 5-Fluorouracil [57], suggesting that miR-21
is involved in development of drug resistance in cancer
chemotherapy. Caudal-type homeobox 1(CDX1) is a
transcription factor playing a key role in regulating stem
cell differentiation to enterocytes. Loss or reduction of
CDX1 expression due to promoter methylation was
found in colorectal cancer cell lines [58–60]. In a recent
publication, Jones et al. identified that miR-215 tran-
scription is directly targeted by CDX1, and miR-215 then
targets to regulate CDX1-downstream genes. Together
with other studies, they proposed that miR-215 could
offer a novel method to specifically target CSCs [61].
Cell communications through microRNAs
Cells, either within the same tissue or in different tis-
sues/organs, need to communicate each other to coord-
inate their behaviors in order to growth, development
and survival. Traditionally, cell communication is under-
stood to be accomplished through activation of receptors
by a variety of chemical and mechanical signals. Recent
studies discovered that miRNAs (e.g., miR-451) can be
secreted by various cells and transported to other cells
via circulation to affect behaviors of recipient cells in
long distance. This provides evidence that cells can com-
municate in long distance by sending genetic materials/
information from one cell to another. Those miRNAs
found in circulation (e.g., in plasma) are relatively pretty
stable resistant to RNase degradation even under harsh
conditions and a long-term (over 10 years) storage,
suggesting that those miRNAs are protected by certain
mechanisms [10, 62]. The high stability of the extracellular/
circulating miRNAs provides the molecules a desirable
characteristic for long distance cellular communication
via the circulation systems. Several factors are contribut-
ing to the stability of those miRNAs, including being
packed into exosomes or microvesicles, being loaded into
high-density lipoprotein and being bound by AGO2 pro-
tein [63–66]. Exosomes, microvesicles, and apoptosis bod-
ies are found in transporting miRNAs for cellular
communications. For example, miRNA-containing exo-
somes are released from mesenchymal stem cells (MSCs)
for communications. This includes miR-133b secreted
from MSCs and transported to neural cells via exosomes
to regulate neurite outgrowth [67], and miR-223 delivered
to cardiomyocytes by MSC-derived miR-223 rich exosomes
to downregulate Sema3A and Stat3 for cardio-protection
in sepsis [68]. For further details in this topic, please see a
recent review [69].
Notions of future miRNA research related to stem cells
Because a minimum of only 6 bp miRNA:mRNA match
(seed sequence) is necessary for a miRNA to exert its
regulatory function, and in humans, approximately 2000
miRNAs are identified and more novel miRNAs are be-
ing discovered, it is expected that miRNAs are involved
in regulation of massive number of genes. The import-
ance of miRNAs in stem cell fate determination and
differentiation has become nearly ubiquitous. With the
progress of the miRNA research, new functions of
miRNAs in stem cells will be uncovered and miRNA-
based techniques for regenerative medicine may be
invented.
Although cell reprogramming with miRNAs was suc-
cessfully achieved in several reports, there is a controversy
whether miRNAs alone can induce the reprogramming or
can only improve the efficiency on traditional reprogram-
ming factors [70]. Future studies need to be carried out
to clarify the controversy. Furthermore, the mechanism
of such miRNA-mediated reprogramming is not fully
understood. A recent publication reported that miRNAs
likely can modulate N6-methyladenosine (m6A) levels of
mRNAs by regulating METTL3 methyltransferase binding
to mRNAs, and such m6A modification can affect cellular
reprogramming to pluripotency [71]. Future studies
should continue to gain a better understanding of the role
of miRNAs in cell reprogramming, as well as in stem cells
regulation and activities.
As more novel miRNAs that can be used for cellular
reprogramming are discovered and high efficient miRNA
delivery methods become available, better methods for
cellular reprograming using miRNAs will be established.
Pluripotent stem cells have been shown high tumorogenesis
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after transplantation due to their pluripotency, which is a
critical threat for tissue regeneration. Given that the
miRNAs are involved in many stages of differentiation, per-
haps, a safer approach is to reprogram somatic cells into
partially committed stem cells with miRNAs. Such partially
committed cells may be multipotent or unipotent, and
should be safer than pluripotent iPSCs for regeneration
applications. Furthermore, it may directly reprogram the
cells into the desired cell types with miRNAs as demon-
strated by using miRNA-302/367 cluster and cell-specific
miRNAs to reprogram fibroblasts into neurons [72].
It is believed that the circulating miRNAs are involved
in cell communications. However, the full functions of
the secretory miRNAs are poorly understood. Some
studies have shown their pivotal roles in disease develop-
ment. One of the important aspects in miRNA field is to
define the roles of those circulating miRNAs, as well as
how to use/control them for therapeutic applications. It
is possible to develop methods for efficiently and sys-
tematically delivery of miRNAs to control proliferation
and differentiation of stem cells for systematic-multiple
tissue repairs. This may be done by mimicking stable
exosomal miRNAs for delivery of therapeutic miRNAs
to regulate or promote proliferation and differentiation
of endogenous stem cells for tissue regeneration or re-
pair systematically. In connection with this, exogenous
miRNAs from plants or milk were found in the serum
and tissues of mice and humans, for instance, the
discovery of the rice specific miR-168a in mouse liver to
regulate the expression of low-density lipoprotein receptor-
associated protein-I [73], implying that miRNAs can be
transmitted from dietary sources. Thus, it is possible to for-
mulate drugs or dietary supplements of certain miRNAs to
intervene the endogenous stem cells for tissue turnover or
tissue repair.
It is known that stem cells can move into wounded or
injured sites for repairing the damaged or diseased tis-
sues. Stem cell recruitment into the affected tissues is
accomplished through chemoattractants released by the
tissues interacting with the chemoattractant receptors
on the stem cells. While many chemoattractants have
been reported to recruit MSCs [74], stromal cell derived
factor-1α (SDF-1α) is the most prominent stem cell
homing factor [75, 76]. Release of SDF-1α creates a con-
centration gradient to promote CXCR4 (SDF-1α recep-
tor)-mediated stem cell mobilization and recruitment
[77, 78]. Precise regulation of stem cell movement is crit-
ical in maintaining stem cell homeostasis within tissues. It
was reported that miRNAs can regulate expression of
SDF-1α (by miR-27b, miR-126, miR-126*) or CXCR4 (by
miR-150), and thus miRNAs participate in regulation of
stem cell recruitment [79–81]. Given that circulating
miRNAs are stable and can function in cell communi-
cations, it would be interested to study if miRNAs
can directly serve as signals to recruit stem cells to
the injured or diseased tissues.
Because one miRNA can regulate expression of many
genes, miRNAs are easily interwoven into regulatory
networks in controlling cell fate and differentiation.
Given that the function of circulating miRNAs in cell
communication, miRNAs may not only involve in cross-
talk between different molecular pathways within a stem
cell or stem cells within a tissue, but also participate in
crosstalk of the pathways in tissue-derived stem cells in
different tissues or organs. This will become clear as the
progress of miRNA research in the future.
Conclusion
In conclusion, miRNAs are short non-coding RNAs
generated from transcripts of genomic DNA. A minimal
of 6 bp seed sequence of miRNA:mRNA match is
necessary to activate RNA interference pathways to
exert post-transcriptional regulation, and such imper-
fect match mode of action of miRNAs allows one
miRNA to regulate many genes and many genes to be
regulated by one miRNA. Thus, it would not be sur-
prised to see that miRNAs are critical in regulating
diverse aspects of stem cells. miRNA has become an
important field of biology and biomedical research in-
cluding improvement of miRNA detection, therapautic
application of miRNAs and studying the mechanisms of
miRNA regulation. With the progress of the miRNA
research, cutting-edge methodology in applications of
miRNAs will be developed in cell reprogramming for
generation of iPSCs and in controlling stem cell prolif-
eration and fates for tissue regeneration and tissue en-
gineering, as well as development of miRNA based
methods for cancer prevention and treatment.
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